<DOC>
	<DOCNO>NCT02093026</DOCNO>
	<brief_summary>This study assess long-term safety efficacy repeat treatment course rituximab , combination methotrexate disease-modifying anti-rheumatic drug ( DMARD ) inadequate responder population participant previously randomize study WA16291 ( NCT02693210 ) WA17043/U2644g ( NCT00074438 ) . The study permit multiple re-treatments protocol-defined end-of-treatment date ( 31 December 2011 ) . Participants enter safety follow-up ( SFU ) period least 48 week . This provide least 7 year follow-up data participant initially randomize WA16291 WA17043/U2644g . Approximately 600 participant potentially eligible enter open label extension study respective feeder study .</brief_summary>
	<brief_title>Extension Study Assess Efficacy Safety Repeat Treatment With Rituximab ( MabThera ) Participants With Active Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>participant active RA complete 24 week treatment WA16291 WA17043 eligible retreatment , base clinical symptom ( Disease Activity Score 28 joint &gt; =2.6 ) females childbearing potential use reliable contraception participant participate rituximab study WA16291 WA17043 withdraw safety followup phase trial previous rituximab nonresponders current treatment diseasemodifying drug ( apart methotrexate ) , antitumor necrosis factor alfa , antiinterleukin1 , biologic therapy participant know active infection kind evidence new uncontrolled concomitant disease development new contraindication would preclude repeat treatment rituximab history severe allergic anaphylactic reaction humanize murine monoclonal antibody female participant pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>